Saint Petersburg, FL, Feb. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Apotheca Biosciences (OTC PINK: PCFP), a biopharmaceutical company, which engages in discovering, developing, and commercializing cannabinoid-based medicines for Opioid crisis, Neuropathic pain, Cancer, Alzheimer's, Parkinson, Sleep disorder and Immune Enhancement, announces today that it has elected Dr. P.C. Sundar as its Chairman & CEO effective February 1, 2019. Dr. Sundar, through his years of experience working for Fortune 100 pharmaceutical companies, will lead the Company in discovering, developing, and commercializing cannabinoid-based medicines for Opioid crisis, Neuropathic pain, Cancer, Alzheimer's and Parkinson.
Dr. Sundar has over 30 years’ executive leadership experience in the pharmaceutical industries. As the CEO of Apotheca, he brings expertise in growing and scaling businesses, developing winning strategies, operations, marketing, sales and innovation for global businesses and broad brand portfolios. During his 30-year career at Abbott Labs, and Bayer, Sundar held positions of increasing responsibility with strong proven results. Before joining the Apotheca team, Sundar most recently served as a Senior Vice President of a Fortune 50 pharmaceutical company. He has brought several FDA-approved drugs to market. He also built several collaborative ventures for these companies. Sundar's experience in the pharma sector is helping Apotheca to be a lead player in endocannabinoid drug discovery. Sundar earned his PhD degree from Vanderbilt University.
Apotheca is positioning to be a world-class research and development facility in endocannabinoid drug development. Apotheca plans to set-up a state-of-the-art research and development lab to enhance the BPRx platform and rapidly expand its research capabilities. Apotheca's research includes specific programs for Alzheimer's disease, frontotemporal dementia, Parkinson's disease and severe, chronic pain. For each of these diseases, there is a dire need for new therapies. Depending on the disease, our therapies will use a BPRx platform to optimize the synergistic combination of photo and endocannabinoids to modulate disease pathology and progression. By significantly decreasing the production of relevant signaling and causative molecules at targeted sites within various tissue systems, the goal is to address the underlying biology of the disease and make a meaningful difference for patients. Our talented team of scientists, scientific advisers, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Apotheca Biosciences is at the forefront of medical technologies with the development of a CBD pain patch for the healthcare and consumer care industry. This acquisition will provide knowledge and expertise to the development of this CBD product, along with our other products. Our pipeline of products includes transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid business strategy ensures focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our strategy and research. For more information on Apotheca Biosciences, please visit www.apothecabio.com
About Apotheca Biosciences Inc.
Apotheca Biosciences, a biopharmaceutical company, through its divisions, engages in 1) the discovery, development, and commercialization of therapies for the treatment of opioid addiction, sleep disorder, PTSD. Alzheimer's and inflammatory diseases worldwide, 2) develops and manufactures medical devices for precise dosing, and 3) direct to business and consumer CBD enhanced supplements, formulations and cosmetics. The pipeline of products includes, transdermal, sublingual, digestive technologies and medical devices for precise and controlled dosing of cannabinoids. Products such as CannaDERME, a transdermal technology using nano-emulsion for fast absorption of cannabinoid compounds for the general pain market.
To request further information about Apotheca, please email info@apothecabio.com, or visit its website at http://www.apothecabio.com/, or visit it on FB @apotheca and Twitter @apotheca
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.